Actuate Therapeutics (NASDAQ:ACTU) Receives Sell (D-) Rating from Weiss Ratings

Key Points

• Actuate Therapeutics has retained a "sell (D-)" rating from Weiss Ratings, while other analysts are more optimistic, with some granting a "buy" rating and a price target of $20.00.
• The company's stock is currently priced at $7.15, with a 12-month low of $5.47 and a high of $11.99, indicating volatility.
• Institutional investors have shown increased interest, with notable stakes acquired by firms like Bank of America and Voss Capital increasing their holdings significantly in the second quarter.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by stock analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

A number of other research analysts have also weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of Actuate Therapeutics in a research note on Tuesday, September 23rd. Wall Street Zen raised shares of Actuate Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, September 20th. Finally, B. Riley initiated coverage on shares of Actuate Therapeutics in a research report on Tuesday, August 26th. They issued a "buy" rating and a $20.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $20.33.

Actuate Therapeutics Stock Performance

ACTU traded up $0.11 during trading on Wednesday, reaching $7.15. The company had a trading volume of 27,835 shares, compared to its average volume of 68,504. Actuate Therapeutics has a 12 month low of $5.47 and a 12 month high of $11.99. The business's fifty day moving average price is $7.59 and its 200 day moving average price is $7.91.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.11).

Institutional Trading of Actuate Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE raised its position in Actuate Therapeutics by 61,068.0% during the second quarter. Bank of America Corp DE now owns 15,292 shares of the company's stock worth $93,000 after acquiring an additional 15,267 shares in the last quarter. Voss Capital LP increased its holdings in shares of Actuate Therapeutics by 101.0% in the second quarter. Voss Capital LP now owns 286,140 shares of the company's stock valued at $1,748,000 after purchasing an additional 143,759 shares during the last quarter. New York State Common Retirement Fund acquired a new position in shares of Actuate Therapeutics in the second quarter valued at $105,000. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Actuate Therapeutics by 492.6% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 18,518 shares of the company's stock valued at $113,000 after purchasing an additional 15,393 shares during the last quarter. Finally, BIOS Capital Management LP increased its holdings in shares of Actuate Therapeutics by 0.7% in the second quarter. BIOS Capital Management LP now owns 9,965,079 shares of the company's stock valued at $60,887,000 after purchasing an additional 71,428 shares during the last quarter.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.